| Q42110909 | 1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis |
| Q36165445 | A dual role for NOTCH signaling in joint cartilage maintenance and osteoarthritis |
| Q34001530 | A new strategy to deliver synthetic protein drugs: self-reproducible biologics using minicircles |
| Q37438928 | A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner |
| Q42147323 | A novel intrinsically disordered outer membrane lipoprotein of Aggregatibacter actinomycetemcomitans binds various cytokines and plays a role in biofilm response to interleukin-1β and interleukin-8. |
| Q87335186 | A significant induction of neutrophilic chemoattractants but not RANKL in synoviocytes stimulated with interleukin 17 |
| Q49212938 | Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice |
| Q33745638 | Attenuation of collagen-induced arthritis in mice by salmon proteoglycan |
| Q104461446 | Beneficial effects of Vigna angularis extract in osteoporosis and osteoarthritis |
| Q35614331 | Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases |
| Q38593977 | Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts |
| Q58774487 | Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications |
| Q36154208 | Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies |
| Q40736447 | Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection. |
| Q33563068 | Bone remodelling markers in rheumatoid arthritis. |
| Q35092924 | Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine |
| Q37464427 | Breaking old paradigms: Th17 cells in autoimmune arthritis |
| Q41825226 | CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis |
| Q38115190 | Can bone loss in rheumatoid arthritis be prevented? |
| Q39361224 | Cellular and molecular pathways of structural damage in rheumatoid arthritis |
| Q54302205 | Citrullinated vimentin stimulates proliferation, pro-inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast-like synoviocytes in rheumatoid arthritis. |
| Q35003674 | Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies |
| Q61805448 | Crataegus Aronia protects and reverses vascular inflammation in a high fat diet rat model by an antioxidant mechanism and modulating serum levels of oxidized low-density lipoprotein |
| Q37987351 | Current understanding of rheumatoid arthritis therapy |
| Q27682535 | Discovery and characterization of olokizumab |
| Q52690942 | Disruption of the mouse Slc39a14 gene encoding zinc transporter ZIP14 is associated with decreased bone mass, likely caused by enhanced bone resorption. |
| Q50017226 | Dual neutralization of TNFR-2 and MMP-2 regulates the severity of S. aureus induced septic arthritis correlating alteration in the level of interferon gamma and interleukin-10 in terms of TNFR2 blocking |
| Q39881401 | Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis |
| Q37806615 | Emerging MRI methods in rheumatoid arthritis |
| Q37584714 | Etanercept-Synthesising Mesenchymal Stem Cells Efficiently Ameliorate Collagen-Induced Arthritis |
| Q38949476 | F-spondin inhibits differentiation of clastic precursors via lipoprotein receptor-related protein 8 (LRP8). |
| Q39019996 | Fibroblasts isolated from a keratocystic odontogenic tumor promote osteoclastogenesis in vitro via interaction with epithelial cells |
| Q39984572 | Flesh-eating Streptococcus pyogenes triggers the expression of receptor activator of nuclear factor-κB ligand |
| Q37783364 | GP130 cytokines and bone remodelling in health and disease |
| Q48140227 | Glucosamine oral administration as an adjunct to hyaluronic acid injection in treating temporomandibular joint osteoarthritis |
| Q38244166 | HIV infection, bone metabolism, and fractures. |
| Q27010898 | HIV: inflammation and bone |
| Q53093209 | IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. |
| Q34248105 | IL-6 in inflammation, immunity, and disease |
| Q30439206 | IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia |
| Q33799161 | IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity |
| Q53464291 | IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model. |
| Q44261383 | IL-6 trans-signaling enhances CCL20 production from IL-1β-stimulated human periodontal ligament cells |
| Q37949664 | IL-6/IL-6 receptor system and its role in physiological and pathological conditions |
| Q52647587 | Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. |
| Q58801220 | Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses |
| Q37965754 | Immunotherapeutic implication of IL-6 blockade |
| Q98177673 | In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease |
| Q42176661 | Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients |
| Q39637547 | Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor κB ligand |
| Q40105940 | Interleukin (IL-6) Immunotherapy |
| Q39314776 | Interleukin 17 is a chief orchestrator of immunity |
| Q41482320 | Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro. |
| Q53327148 | Interleukin-29 induces receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes via MAPK signaling pathways. |
| Q36084929 | Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis |
| Q60916226 | Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma |
| Q90117830 | Interleukin-6 inhibition in the management of non-infectious uveitis and beyond |
| Q54324742 | Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. |
| Q48147981 | Interplay between low plasma RANKL and VDR-FokI polymorphism in lumbar disc herniation independently from age, body mass, and environmental factors: a case-control study in the Italian population. |
| Q60918210 | KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis |
| Q37150420 | Kinetics and interplay of mediators of inflammation-induced bone damage in the course of adjuvant arthritis |
| Q42068905 | Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2. |
| Q40376112 | Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats |
| Q37375129 | Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 β -induced RANKL, OPG, TNF α , and IL-6 expression in human rheumatoid synoviocyte MH7A. |
| Q38601750 | Muscle Paralysis Induces Bone Marrow Inflammation and Predisposition to Formation of Giant Osteoclasts |
| Q42938295 | Non-genomic action of TCDD to induce inflammatory responses in HepG2 human hepatoma cells and in liver of C57BL/6J mice |
| Q36480992 | Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss |
| Q40235356 | Osteoclastogenesis induced by CHIKV-infected fibroblast-like synoviocytes: a possible interplay between synoviocytes and monocytes/macrophages in CHIKV-induced arthralgia/arthritis |
| Q64236844 | Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis |
| Q35572441 | Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection |
| Q64079860 | Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases |
| Q61792382 | Paracrine-mediated differentiation and activation of human haematopoietic osteoclast precursor cells by skin and gingival fibroblasts |
| Q89944986 | Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice |
| Q92067504 | Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study |
| Q27022976 | Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor |
| Q33692037 | Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis |
| Q33554023 | Promising bone-related therapeutic targets for rheumatoid arthritis |
| Q96298714 | Pulp stem cells with hepatocyte growth factor overexpression exhibit dual effects in rheumatoid arthritis |
| Q64096832 | RANKL is a therapeutic target of bone destruction in rheumatoid arthritis |
| Q50207113 | RANKL: A therapeutic target for bone destruction in rheumatoid arthritis |
| Q37358099 | Recent advances in neutralizing the IL-6 pathway in arthritis. |
| Q39495372 | Reciprocal osteoblastic and osteoclastic modulation in co-cultured MG63 osteosarcoma cells and human osteoclast precursors. |
| Q54110138 | Regulatory effect of anti-gp130 functional mAb on IL-6 mediated RANKL and Wnt5a expression through JAK-STAT3 signaling pathway in FLS. |
| Q36903327 | Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes |
| Q89896777 | Rheumatoid arthritis: TAK-ing the road to suppress inflammation in synovial fibroblasts |
| Q91782570 | S1P-S1PR1 Signaling: the "Sphinx" in Osteoimmunology |
| Q42578542 | Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis |
| Q37315782 | Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q88592126 | Soluble Tumor Necrosis Factor Alpha Receptor 1, Bone Resorption, and Bone Mineral Density in the Year Following Hip Fractures: The Baltimore Hip Studies |
| Q28076558 | Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date |
| Q38411334 | Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis |
| Q39415136 | T-helper 17 cells mediate the osteo/odontoclastogenesis induced by excessive orthodontic forces |
| Q30396344 | TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction |
| Q38625497 | TNF-α-induced miR-155 regulates IL-6 signaling in rheumatoid synovial fibroblasts |
| Q64118169 | Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib |
| Q92712185 | The Autophagy in Osteoimmonology: Self-Eating, Maintenance, and Beyond |
| Q51720215 | The Pro-inflammatory Cytokine Interleukin-6 Regulates Nanoparticle Transport Across Model Follicle-Associated Epithelium Cells. |
| Q59793706 | The Two-Faced Cytokine IL-6 in Host Defense and Diseases |
| Q39311198 | The growth and osteoclastogenic effects of fibroblasts isolated from keratocystic odontogenic tumor |
| Q54379042 | The p38-mediated rapid down-regulation of cell surface gp130 expression impairs interleukin-6 signaling in the synovial fluid of juvenile idiopathic arthritis patients. |
| Q38685086 | The role and therapeutic targeting of IL-6 in rheumatoid arthritis. |
| Q39248512 | The role of stromal cells in inflammatory bone loss |
| Q35429154 | The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis |
| Q39350335 | Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation |
| Q35724900 | Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions |
| Q38044757 | Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
| Q60300744 | Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection |
| Q38237564 | Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights |
| Q37358242 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis |
| Q34974033 | Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion |
| Q64102242 | Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System |